Guideline-Recommended Treatments for HER2-Low Metastatic Breast Cancer

Treatment for HER2 low metastatic breast cancer may utilize HER2-targeted antibody-drug conjugates like T-DM1 and sacituzumab govitecan after initial therapy; knowing HER2 status, even low expression, is critical to guide use of these HER2-directed ADCs after chemotherapy.